comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-01 17:35:26 - browse：2977

Matts Take Column Illustration — Molly Ferguson for STAT

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 medicines.

That could have a big, positive impact on public health, and it will very likely swell the coffers of the pharmaceutical companies that make these medicines, including Wegovy’s maker, Novo Nordisk, and Eli Lilly, now the most valuable drug company in history thanks largely to hopes for its GLP-1, Mounjaro. These are medicines that could save lives, make money, and perhaps reshape our culture. But they are also, we are learning, not without risk.

So what’s next?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Guardant Health colon cancer test endorsed by FDA advisory panel

WSS

Should insurance cover cosmetic surgery?

Prime Medicine, Myeloid Therapeutics clash over genome

Pharma’s losing bet in New Jersey

New research sheds light on how often breast cancer is overdiagnosed

Lawsuit challenges CMS nursing home minimum staffing rule

Keeping primary care docs in field isn't impossible, says AAFP CEO

entertainment

comprehensive

focus

How one medical school became remarkably diverse

Unmasking the 'centricity' illusion in clinical trials

The high cost of giving birth even with insurance

New research sheds light on how often breast cancer is overdiagnosed

Anesthesiologist group: stop taking Ozempic before surgery

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

After affirmative action ruling, medical educators look to 'holistic review'

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Medicare proposal to cover medical devices draws a mixed reaction

Medicare Advantage beneficiaries sue Humana over algorithm use

entertainment

Medicare Advantage beneficiaries sue Humana over algorithm use

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Medicare drug price negotiation hasn't dried up venture capital

Medical students need to learn the potent medicine of empathy

Lawsuit challenges CMS nursing home minimum staffing rule

Carvykti CAR

focus

explore

explore

hotspot